Straits Times Index
3,144.76 -38.85 (-1.22%) S&P 500
5,061.82 -61.59 (-1.20%) Dow
37,735.11 -248.13 (-0.65%) Nasdaq
15,885.02 -290.08 (-1.79%) Bitcoin USD
62,712.41 -3,605.85 (-5.44%) CMC Crypto 200
885.54 0.00 (0.00%)
Rhythm Pharmaceuticals, Inc. (RYTM)
After hours:
| Previous close | 40.33 |
| Open | 40.46 |
| Bid | 40.07 x 200 |
| Ask | 40.24 x 100 |
| Day's range | 39.96 - 41.04 |
| 52-week range | 15.50 - 52.57 |
| Volume | |
| Avg. volume | 611,732 |
| Market cap | 2.411B |
| Beta (5Y monthly) | 1.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.20 |
| Earnings date | 30 Apr 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 58.89 |
Simply Wall St.Market Sentiment Around Loss-Making Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Rhythm Pharmaceuticals, Inc. ( NASDAQ:RYTM ) is possibly approaching a major achievement in its business, so we would...
ZacksModerna (MRNA) Surges 6.2%: Is This an Indication of Further Gains?
Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
GlobeNewswireRhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
-- Proceeds from financing and existing cash on-hand sufficient to fund planned operations into 2026 --BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that it has signed an investment agreement with current shareholders, led by Perceptive Advisors LLC and its Discovery Fund and a life-scienc
